Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: a retrospective study and literature review
IntroductionOff-label rituximab is commonly used for patients with systemic lupus erythematosus (SLE) with extrarenal disease activity.MethodsThe outcomes and tolerability of rituximab in adult patients with non-renal SLE treated at our hospital from 2013 to 2020 were described. Patients were follow...
Main Authors: | Carla Sans-Pola, Immaculada Danés, Josep Àngel Bosch, Patricia Marrero-Álvarez, Josefina Cortés, Antònia Agustí |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-05-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1159794/full |
Similar Items
-
Off-Label Use of Rituximab in Patients with Different Types of Nephropathies in a Tertiary Hospital: A Retrospective Study
by: Carla Sans-Pola, et al.
Published: (2021-10-01) -
Use of rituximab in systemic lupus erythematosus in children: a review
by: A. N. Arefyeva
Published: (2019-11-01) -
Relationship of T regulatory cells content, activity and serum autoantibodies level in patients with systemic lupus erythematosus receiving rituximab
by: A V Torgashina
Published: (2009-04-01) -
Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients
by: O. Capdevila, et al.
Published: (2023-07-01) -
Safety of Drugs Used during the First Wave of COVID-19: A Hospital-Registry-Based Study
by: Cristina Aguilera, et al.
Published: (2022-07-01)